



VYCOR MEDICAL, INC. – BUSINESS SUMMARY

	<u>Page</u>
Highlights	2
Business Description	6
Clinical Benefits of VBAS	8
Cost Benefits of VBAS	10

“Brain retractors were first designed for micro neurosurgery, primarily for vascular lesions where elevation of the brain is critical for surgical treatment. The Vycor Brain Access Retractor System is a major advance in brain retraction for intracranial tumors where lesion isolation within the brain substance is a top priority. A single tubular retractor isolates pathology easily with excellent lighting. The brain is retracted with equal pressure around the isolated lesion margin. The retractor can be easily used with frameless stereotactic systems and is remarkably easy to reposition during tumor resections. I believe the Vycor system is a much-needed upgrade to preexisting retractor systems, particularly for resection of intra axial tumors.”

Donald M. O’Rourke, MD - Associate Professor, Dept. of Neurosurgery University of Pennsylvania

“In my experience, I like the VBAS for brain surgeries, mainly with microsurgical techniques for primary or metastatic brain tumor resections. It allows me not only to approach the tumor with minimal retraction but also with a degree of accuracy and safety as it allows me to visualize surrounding gray and white brain matter. I have experienced less brain edema post-operatively in my patients. This has helped to some extent with a faster discharge for the patients.”

Dr. Ramin Rak, MD
Department of Neurosurgery
North Shore LIJ Huntington Hospital

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the sale of the Company’s securities nor passed upon the adequacy or accuracy of the information contained herein. Any representation to the contrary is a criminal offense. This is not an offer to sell nor a solicitation to purchase securities of the Vycor Medical, Inc. (“Vycor”) in any state where the offer or sale is not permitted. Securities may only be sold in compliance with applicable statutes, rules and regulations, including but not limited to compliance with the Securities Act of 1933. In particular, we may not sell Vycor’s securities until a registration statement filed with the Securities and Exchange Commission is declared effective or pursuant to an applicable exemption from registration. The information contained herein is not complete and may be changed. Vycor undertakes no obligation to update the information contained herein.

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor’s SEC filings. All forward-looking statements attributable to Vycor herein are expressly qualified in their entirety by the abovementioned cautionary statement. Vycor disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law. The recipient acknowledges that Vycor is a publicly traded company. Recipient acknowledges that any confidential information constituting material nonpublic information that Vycor provides to the recipient is being provided to the recipient in reliance upon the agreement that the information will remain confidential. By accepting this material, the recipient acknowledges that it is aware of the applicable requirements of the federal securities laws relating to material non-public information and trading in securities of Vycor



VYCOR MEDICAL, INC. –HIGHLIGHTS

THE COMPANY AT A GLANCE

- Vycor Medical, Inc. (Vycor or the Company) is a medical device company headquartered in Bohemia, NY that designs, develops and markets next generation devices for use in Neurosurgery.
- Vycor has developed its first product, the ViewSite Brain Access System (VBAS), a next generation brain retractor system. This is now fully commercialized and being used in brain surgeries in the US and internationally
- VBAS represents a significant advancement in brain retraction technology, providing an impeccable field of vision, while creating a streamlined working channel and potential for the surgeon to obtain improved surgical outcomes. According to surgeons who have used the device, the VBAS produces less tissue trauma, is less invasive than traditional retraction and provides the surgeon an excellent field of vision.
- Management estimates that VBAS offers potential cost savings for US hospitals of up to \$6,000 per procedure compared to a purchase price of \$595 largely derived from shorter operating theater time (surgeons have estimated 30-60 minutes saving) and potentially reduced post-operative recovery time
- Approx **900** surgeries have been carried out utilizing VBAS. Approx **80** US hospitals have approved VBAS for use or evaluation. Vycor has found that the learning curve is only 1-2 cases for surgeons, who like the simplicity of design and ease of use
- The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries, CE Marking for the European Market and Canadian HPB licensing for brain
- Internationally, Vycor has distribution agreements in place in Canada, the Benelux, Greece, Italy, Spain, and Sweden. The company also has an agreement covering China, pending SFDA approval, and China represents 70% of the whole US market in numbers of VBAS addressable procedures. Over 50 international hospitals have either ordered or are evaluating the product.

VBAS – THE FUTURE STANDARD OF CARE

“THERE’S GOT TO BE A BETTER WAY...”

Brain retraction technology has not changed significantly in over 50 years

1950




Today- Current Standard of Care



<ul style="list-style-type: none"> • To access a surgical site (Target Site) in the brain, surgeon first needs to remove part of the skull (craniotomy) and then part (retract) the soft brain tissue to access the target • Current standard of care utilizes a metal blade retractor to force the tissue apart; to maintain the opening the blades are attached to a head frame and tension is applied • The pressure that is needed can damage the brain tissue and cause bruising (edema) which if prolonged can result in post-operative impairment or brain damage • Low surface area inherent in the design of existing retractors creates these high pressures being exerted as the surgeon pulls the brain tissue apart 	<ul style="list-style-type: none"> • This pulling can also result in the surgical site moving (target shifting), requiring the whole retraction procedure to be repeated • Retraction often causes brain tissue leakage or creeping obscuring visibility, exacerbated by the fact that the blades are not transparent • The need to gain access to the Target Site using standard retractors requires a large craniotomy • Large craniotomy + potential damage + extended post-op recovery = greater costs + potential liability
--	--

VBAS – A LEAP FORWARD AND THE FUTURE STANDARD OF CARE



<ul style="list-style-type: none"> • Device slides smoothly into brain and creates a safe, clear working channel for the procedure to be performed • Specially-designed elliptical shape evenly disperses brain tissue and minimizes localized pressure • Greater surface area reduces pressure points to within safe levels and significantly reduces edema • Large enough channel for standard surgical instruments and compatible with all standard equipment (head frames, IGS) 	<ul style="list-style-type: none"> • Eliminates need for cutting and pulling, minimizing tissue trauma • Improves target accuracy and eliminates target shifting and therefore requirement to reposition brain tissue • Contained working channel prevents tissue “leaking” • Significantly increases field of vision through a clear, visible and stable channel, allowing for continual monitoring of surrounding tissue and structures during surgery
---	--

VBAS SALES: MARKET STRUCTURE AND VYCOR APPROACH

US Addressable Market:

- Approximately 750-1,100 hospitals with a smaller number carrying out the bulk of relevant procedures.
- Approximately 1,500 neurosurgeons focus predominantly on craniotomies and other VBAS-relevant cranial procedures
- Teaching hospitals not only carry out more relevant procedures but also provide a natural way to drive adoption through conversion of new surgeons

Hospital Adoption Process:

- Vycor and/or distributor targets surgeons through: hospital visits, surgeon-to-surgeon referral, trade shows, other marketing
- Surgeons need to be the principle proponent within the hospital, and Vycor has found that the learning curve is only 1-2 cases for surgeons, they like the simplicity of design and ease of use
- Hospital Administration is required to approve purchase of a new product and in many cases even the provision of trial samples, even though VBAS is FDA-approved. Focus is on:
 - Clinical studies, papers and other peer reviews evidencing the clinical benefits of the product
 - Leading hospital adoption, leading surgeon adoption
 - Cost/benefit analysis
 - Product simplicity of use, need for training
- Experience has been that approval process can take up to six months for each hospital, and in some cases may even be longer. However, this time reduces as more leading hospitals become approved and as more clinical paper/studies and other peer reviews are published:
 - Vycor has seen an acceleration in approval times and numbers, and now has approx **80** US hospitals approved for use or evaluation
 - A leading “marquee name” university teaching hospital is submitting for publication an evaluation paper outlining its clinical experience with VBAS and demonstrating the benefits; Vycor believes this will greatly assist the approval process
 - Follow-up work by the same institution and other work Vycor is doing will demonstrate the cost benefits
 - Increased presence by Vycor at key industry trade shows in which leading neurosurgeons participate

Sales and Distribution Strategy:


- Vycor is focusing initially on the larger teaching hospitals and on the larger regions in terms of population and hospitals.
- The Company has operated through the first half of 2010 with agreements in place for regions accounting for only c.50% of the population and targeted hospitals. Targeting to increase this to 80% by year end
- The Company has appointed Thomas Bridges, a veteran sales and marketing executive with over 28 years of experience in the medical device industry, as National Sales Director

International Sales and Distribution Strategy:


- Vycor has obtained CE Mark approval, which enables it to sell product in all European countries, Canadian HPB licensing and has filed for SFDA approval in China
- Vycor’s current approach is to target markets of reasonable size, where the use of disposable devices is a norm, and which are either covered by Vycor’s existing approvals or where local approvals ‘look to’ US FDA or CE Mark and therefore require minimal supplemental approvals.
- In these markets, Vycor’s strategy is to work with distributors with extensive experience in the neuro space, with excellent coverage of surgeons and hospitals in their markets and with the capability to manage their own regulatory, marketing and distribution with minimal input from Vycor
- Vycor currently has distribution agreements in place in Canada, the Benelux, Greece, Italy, Spain, and Sweden. The company also has an agreement covering China, pending SFDA approval, and China represents 70% of the whole US market in numbers of VBAS addressable procedures. The company continually seeks and negotiates with distributors for other international markets

VYCOR MEDICAL – PROGRESS

Last Six Months: Re-established Market Presence

- 
- Closed recapitalization Dec/Jan; \$960,000 raised at \$0.0125, secured ongoing funding commitment.
 - Launched enhanced marketing campaign with distributors, doctors and hospitals. First six months 2010 Vycor had active distributors covering only c.50% of the US. Despite this low coverage VBAS has been approved for use or evaluation in approximately c.80 hospitals (**equivalent to 8% of its total US target hospitals**). This level of penetration represents a significant increase in the last 12 months, highlighting the upside as Vycor increases its network coverage
 - Exhibited at key industry AANS show. Presentations by two leading neurosurgeons from Johns Hopkins and North Shore-LIJ. High level of interest and “buzz” around the product
 - Entered into distribution agreement for China, subject to SFDA approval. China is 70% of the whole US market in numbers of VBAS addressable procedures
 - Entered into distribution agreements covering Canada, Sweden and Australia
 - Commenced active PR campaign with prestige trade and financial publications. Selected recent coverage includes: Surgical Technology International Magazine, June; Military Medical Technology Magazine, June; Wall Street Journal Transcript, April; USA Today, March; Health News Digest, March; Medical Device Daily, March (www.vycormedical.com for links)
 - Closed funding round in May of \$750,000 at \$0.015.



Next Six To Nine Months: Capitalize on Initiatives Already Underway

- 
- Now seeking additional funding through the next milestones
 - Put in place distribution arrangements covering c.70-80-% of US population. New agreements entered into last few months covering an additional 25% of the US population
 - Increase adoption and sales in hospitals that are already using VBAS and increase penetration of target hospitals across distributor base to best-of-breed levels (20% plus)
 - Expected publication of a clinical study by a marquee name teaching hospital; Vycor anticipates this as a key step in enhancing both penetration of new hospitals and increased adoption by existing hospitals as it will provide significant medical credence to VBAS.. It is currently envisaged that the preliminary report will be published in a leading neurosurgical journal.
 - Attain China SFDA approval and commence sales. Vycor and its China distributor will arrange a series of demonstrations by US neurosurgeons of how VBAS can be used and what the benefits are Chinese reps and neurosurgeons.
 - Hire key sales staff; Thomas Bridges, an executive with extensive neuro and operating theater sales experience, appointed as National Sales Director
 - Actively assessing and developing, in partnership with neurosurgeons, new products to address areas in neurosurgery which are currently not sufficiently served, particularly focused on minimally invasive neurosurgical procedures aimed at reducing patient trauma
 - Presenting at national, regional and international neurological trade shows including the key CNS in October
 - Increased penetration, increased adoption, increased sales, enhanced value

Contact Details:

Kenneth T. Coviello
ktcoviello@vycormedical.com

Adrian C Liddell, Chairman
adrian.liddell@fhcpartners.com



BUSINESS DESCRIPTION

Overview:

Vycor Medical, Inc. (Vycor or the Company) is a medical device company headquartered in Bohemia, NY that designs, develops and markets next generation devices for use in Neurosurgery. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries, CE Marking for Europe and Canadian HPB licensing for brain

The Company has developed its first product, the ViewSite Brain Access System (VBAS), a next generation brain retractor system. This is now fully commercialized and revenues generating.


The Company's product addresses a market that has not changed materially in over 50 years in contrast to development in surgical technologies. The existing retractors can cause brain damage and/or prolonged patient recovery with the incidence of contusion or infarction from brain retraction of approximately 10% in cranial surgery and 5% in intracranial procedures. Pressure at the retractor blade tip is said to be responsible for 22% of infarctions as determined by CT scans. Given that there is an estimated 600,000 brain surgeries annually in the US and internationally this amounts to a very sizeable problem and possible addressable market.

Key Highlights:

- Revenue-generating innovative medical device company with approximately 900 surgeries having been carried out utilizing the VBAS brain retractor. Approx 80 US hospitals have approved VBAS for use and purchased product, and many other hospitals are either going through the approvals process or evaluating the product. Over 50 international hospitals have either ordered or are evaluating the product
- According to surgeons who have used the device, the VBAS produces less tissue trauma, is less invasive than traditional retraction and provides the surgeon an excellent field of vision. The VBAS holds the potential for speedier, safer surgeries and a quicker patient discharge. Surgeons using VBAS have indicated that on average operating time is reduced 30-60 minutes in the OR. Furthermore some surgeons have suggested post-operative recovery may be quicker resulting in patients potentially being released as much as 1-2 days earlier resulting in significant cost savings to the hospital
- Vycor has found that the learning curve is only 1-2 cases for the surgeon; they like the simplicity of design and ease of use

Brain Access System (VBAS)

The VBAS series of disposable products are used by the neurological surgeon to access the surgical site. This is done by inserting the VBAS through the brain tissue and then removing the VBAS introducer, leaving the remaining hollow working channel in place to provide the surgeon with access to the precise location desired for surgery



The VBAS is available in multiple sizes and is a single-use product. The current series consist of twelve disposable products, offered in four different port diameters of 17mm and 21mm, 12mm and 28 mm and a choice of three lengths for each of 3, 5, and 7cm. A further broadening of this product range is already underway.



CLINICAL BENEFITS OF VBAS

Background

The VBAS represents the first major game change in brain retractor technology currently being utilized with Craniotomies. The existing retractors that are currently widely used in cranial procedures are antiquated and in fact have hardly changed in over 50 years. The shortcomings of the existing retractors (known as ribbon or blades) are well known and documented and include but are not limited to:

- Excessive Venous Pressure, resulting from the inherent shape of the retractor that has a low surface area and the resultant high focal pressure can result in retraction injuries. Pressure at the retractor blade tip is said to be responsible for 22% of infarctions as determined by CT scans (*Rosenorn J. 1987*)
- Target Shift resulting from the need to pull the brain tissue to gain access to the target. This also can lead to leakage and damage of healthy surrounding tissue. Even with Image Guided Surgery Systems (IGS) the retraction system is often cumbersome
- Limited Visibility of surrounding tissue compounds the need to reposition retractors during lengthy procedures
- Retraction Injury. The incidence of contusion or infarction from brain retraction is approximately 10% in cranial base procedures and 5% in intracranial aneurysm procedures (*Andrew R S, Bringas J R. 1993*)

Cognizant of these shortcomings the industry participants (such as Cardinal Health, V. Mueller, Aesculap, Integra Life Science and Codman (Division of J&J)) have tried to try and address some of these issues by adding technologies to the existing product such as:

- Pressure monitoring devices
- Various types of plastic and silicone coatings to reduce retraction injury
- Variations in the metals of the retractors (a “softer” type than hard metal)

However Vycor management strongly believes that only a complete rethink of the retractor product can properly address all these issues. Vycor has done just that with its VBAS product line. The VBAS design and use are patent applied for and pending in the US and multiple international jurisdictions.

VBAS benefits over existing retractor technologies

Benefits of the VBAS system for the patient, surgeon and hospital are numerous and are supported by field reports from surgeons who have used the device, a recently published article in Surgical Technologies International and the growing hospital customer list. Below we outline some of the key advantages it has over the existing retractor technologies:

1. Reduction of Venous Pressure

Normal surgical procedures utilizing standard retractors require the pulling away of healthy tissue to expose the target site. Current retractors have low surface areas that in turn lead to high focal pressure. This increased venous pressure can at times exceed safe levels. Prolonged venous pressure may lead to permanent brain damage and/or post operative delays in recovery (see Cost Benefits of VBAS, below).

With the VBAS local surface pressure is minimized due to the increased surface area of its elliptical shape. The shape of the device is key. The VBAS was designed to evenly disperse the brain tissue so there is no focal pressure that is exceeded at any given point, significantly reducing leakage that otherwise would occur. The lack of sharp edges on the VBAS that are inevitably present in current retraction systems avoids severe traumatization of the retracted tissue. Most existing retractor injuries occur not under the retractor blade but under the edge of the retractor where the gradient of pressure is highest. Efforts to address this by adding pressure monitoring devices to the retractor however, while helpful doesn't address the inherent high focal pressure caused by the shape of the

device. VBAS solves this by eliminating the retraction edges altogether and thereby reducing iatrogenic trauma.

2. Superior Field of View

The VBAS is made of polished polycarbonate. The transparency of the device allows for the continual monitoring of the surrounding tissue and structures during surgery. The optical clarity of the polished Polycarbonate provides significantly superior viewing of the surrounding tissue to easily detect any bleeding that may occur immediately. Standard retractors and the cotton or foam materials used in unison are opaque so should bleeding occur it is not recognized until the end of the procedure when the retractor and materials are removed or when there is a sudden shift in the patient's vitals.

Surgeons have also found they do not suffer from the light absorption or reflection experienced with other retractors, thus providing much superior vision of the pathology.

The elliptical shape of the VBAS allows a 360 degree distribution of the brain tissue similar to the effect of a round device while providing a widened working channel in one axis to give a better field of view and working room while keeping the other axis smaller to be less invasive. The clear nature of the VBAS means that as the working channel port is inserted, oncoming vessels can be seen through the optically clear introducer and avoided. Furthermore the transmission of electrocautery energy is not possible with the plastic devices, which also eliminates the risk of burning the exposed tissues.

3. Reduction in Target Shift

Normal surgical procedures utilizing standard retractors require the pulling back of healthy tissue to expose the targeted site. The degree of pulling results in the target area to shift away from what is seen on the IGS system. This shifting of the target requires the surgeon to cause additional trauma to healthy tissue and spend time repositioning the retractors as they work towards re-locating the target.

With the VBAS there is no target shift as the elliptical shape distributes uniform pressure to the surrounding brain tissue. The VBAS has the opportunity to adopt entirely to IGS Systems – allowing the surgeon to see the target without experiencing any shift in its location. In fact with the IGS-enabled VBAS the tip of the introducer serves as the pointer on the IGS System, meaning that the surgeon knows his exact location in the brain during the entire procedure.

4. Minimization of Size of the Craniotomy-Less Invasive Procedure

The shape of the VBAS coupled with its transparency allows for the continual monitoring of the surrounding tissue and structures to the target. This combination enables the surgeon to exactly target a specific area and not unnecessarily damage surrounding just to gain better access to the target area unlike with standard retractors. To give an indication of the significance of this one should consider that in a “typical” brain procedure using standard blade retractors in a procedure involving the removal of a 7cm cystic astrocytoma, an access site (corticotomy) of approximately 20mm would be required. However, the same procedure performed utilizing the Company's VBAS product requires a corticotomy of only 2mm.

COST BENEFITS OF VBAS

Cost Benefits of VBAS:

A typical Craniotomy is reimbursed at 40% of an average billed cost of \$115,000¹, with fixed allowances for surgery, post op recovery etc. Retractors, along with OR consumables, are not reimbursed as specific devices.

The VBAS is able to potentially offer significant savings for each case in three areas: OR consumables; OR time; post-operative recovery time. These potential savings are driven primarily by the key clinical advantages of VBAS that have been discussed above:

- Rapidity of set-up, ease of use, reduced target-shifting
- Less invasive surgery, smaller craniotomy required
- Less patient trauma, lower edema and therefore shorter post-op recovery

The table below sets out a summary of the potential cost savings which have been estimated by Vycor management in discussion with neurosurgeons who have used the device, hospital administrators and neurosurgery device distributors (full breakdown available)². These are potential savings, not all of which will be relevant for every procedure. The company plans to quantify the cost benefits of the VBAS product over current retractor technology with surgeons who have direct experience with using VBAS, the outcome of which cannot be assured at this time.

OR Consumables Savings	Amortization/re-sterilization of existing blades; cottonoids; savings on titanium plate and screws (smaller craniotomy):	\$320
OR Theatre Time Saving	30 – 60 minute saving from average 3-4 hour procedure – assume 30 mins:	\$2,000
Post Op Recovery Saving	1-2 day less stay in hospital post operation – assume 1 day:	\$4,400
VBAS Cost	Actual average cost to hospital	\$(595)
POTENTIAL NET SAVING TO HOSPITAL PER PROCEDURE		>\$6,000

¹ Source: HealthGrades cost index and Pharmetrics, Inc.

² Not all items in the table would be relevant in each procedure performed


Other Products:

Cervical Access Products (VCAS):

The Company has also developed a spine product which has a similar size market potential as VBAS. It already has 510k approval with patents pending. A second generation prototype is in the early stages of development. The product has similar benefits to the VBAS for anterior cervical procedures of the spine. Development of VCAS is conditional upon successful market testing of prototypes and field testing, and on additional funding.

The Cervical Access System products are to be used by the neurological surgeon to access the Anterior cervical surgical site (the uppermost vertebrae located in the neck). This type of surgery is near very critical and delicate structures such as the larynx, esophagus and carotid artery. The shape of the Cervical Access System with the introducer lets the surgeon carefully place the Device and the unique anchor screws then safely hold the access channel in place during the procedure. The clear body of the retractor will allow the surgeon to see the entire field both during the insertion process as well as throughout the surgical procedure.

The VCAS will initially be developed for this sole procedure, although Vycor would intend to expand the range of spine products to encompass a much wider range of spine neurosurgery procedures, conditional upon the success of the initial VCAS models.



Other:

Management believes that key characteristics of the technology, visibility and minimal insertion trauma are significant advantages in the design of VBAS and VCAS, which may be applicable to other types of surgery such as abdominal and breast.

Management also intends to pursue a strategy of adding to its neurosurgery product portfolio through acquisition and in-licensing of products which it believes to be complementary to its strategy and existing and planned portfolio

The Market:

Vycor management have analyzed and estimated the market for its products from extensive analysis of available statistics, discussion with surgeons, distributors and other market participants. Vycor is currently focusing its attention for VBAS on the US, China and Europe and so has not estimated the market potential from future ROW markets. Statistics for VCAS are on a more general, global basis, but are only for anterior cervical surgery. The Addressable Market in both cases is being addressed by both current and planned VBAS and VCAS product line extensions

VBAS

	USA	China	Europe	Total
VBAS Applicable Procedures	304,000 ⁽¹⁾	300,000 ⁽³⁾	285,000 ⁽⁴⁾	889,000
VBAS Addressable Market	213,000 ⁽²⁾	150,000 ⁽³⁾	200,000	563,000
VBAS Potential Market	\$127m	\$45m	\$30m	\$202m

(1) National Neurological Procedure Statistics 2006 Survey, AANS

(2) Vycor estimate that 70% of VBAS Applicable Procedures provide the Addressable Market once new sizes and shapes are added

(3) According to Devon International

(4) Vycor management estimate based on US/European population and healthcare budget statistics

VCAS

	USA	ROW	Total
Annual Spinal Procedures ⁽¹⁾	1,345,000	1,500,000	2,845,000
VCAS Addressable Market ⁽²⁾	295,000	328,000	623,000
VCAS Potential Market	\$147m	\$164m	\$311m

(1) AANS

(2) Vycor management estimate that 22% of Spinal Procedures would be addressable by planned VCAS instruments pending successful development and field testing

IP Protection:

Vycor has filed domestic and international design and method patents on both brain and spine products. The Company has received FDA 510K clearance for the USA, the CE mark in Europe, and a Canadian License. The Company is also ISO 13485:2003 Certified and registered with the US FDA as a Device Establishment. The up-to-date details on each filing are provided in the Company's quarterly and annual filings with the SEC.

Sales Strategy:

VBAS was launched in November 2008 with a clear strategy of driving sales through leading luminary neurosurgeons to help drive the product as a key part of their sales strategy. Hospital Administration is required to approve new products or trials of the device (including free samples), negotiate pricing and issue approvals to order. The Company is adopting a dual strategy of targeting both the leading neurosurgeons and the hospitals. The Company believes that out of the 4,500 neurosurgeons in the US approximately 1,500 focus predominantly on craniotomies or cranial procedures that would benefit from the VBAS product. Management believes that there are approximately 750-1,000 hospitals that represent their addressable market with a smaller representing the bulk of the craniotomies performed. It is this initial universe where the management is focusing its initial efforts.

To this end Vycor has focused its sales efforts in establishing relationships with key reference surgeons and Hospitals. To date it has developed relationships with over 200 prominent neurosurgeons and over 80 hospitals directly or through their distributors.

Vycor in addition has contracted with a combination of stocking and non-stocking distributors in the US providing it with an indirect sales force of more than 80 experienced sales people. Each of the distributors has existing relationships with neurosurgeons and comes with extensive years of focus in the neurosurgery sector.

The table below sets out a summary of Vycor's status with its US hospital customer and target base, and a list of the hospitals that have placed orders is provided at the end of the document

Surgeries carried out using VBAS	900 approx
Hospitals who are approved and have placed billable orders	80 approx
International hospital who have ordered or are evaluating	>50 approx

In Europe, the company is using three exclusive stocking distributors who are also focused in neurosurgery. In China – a market Vycor estimates is on its own 70% the size of the US in terms of addressable procedures – Vycor has entered into a distribution agreement with a distributor, subject to receiving SFDA approval.

Competition:

The current standard of care in brain retractors has not changed much since their fundamental design from the 1920's since ribbon type blades are still used today. Research shows that most of the more recent advancements have focused on adding technology to this type of retractor such as pressure monitoring devices and various types of plastic or silicone coating so that retraction injury might be limited. Other advancements have included variations in the metals of the retractors, some of these being relatively soft as compared to previous iterations, in an attempt to limit retraction injury.

Vycor Brain Access System products represent a significant improvement over existing products. The current major manufacturers of brain retractors, and accordingly, the Company's competitors are:

- Cardinal Health (V. Mueller line)
- Aesculap

- Integra Life Science
- Codman (Division of Johnson & Johnson)

The Cervical Access System key competitors are Medtronic, Asculap/B. Braun, Cardinal, Nuvasive, Cloward Instruments and others. In addition to the standard “blade retractors” distributed by the companies listed above, Medtronic distributes the MetRx dilating retractor system. In addition companies such as Endius and EBI have announced cervical retractor systems.

Vycor Medical Advisory Board:

The Company benefits from a high profile advisory team

Neurosurgeon	Expertise	Professional Affiliations
Dr. David Langer	<ul style="list-style-type: none"> ▪ AVMs ▪ Aneurysms ▪ Minimally Invasive Spine Surgeries 	<ul style="list-style-type: none"> ▪ Director of Cerebrovascular Neurosurgery at St. Luke's-Roosevelt, Beth Israel and Long Island College Hospitals (New York, NY) ▪ Assistant Professor of Neurological Surgery at Albert Einstein College of Medicine (New York, NY)
Dr. Konstantin Slavin	<ul style="list-style-type: none"> ▪ Stereotactic and Functional Neurosurgery ▪ Tumors 	<ul style="list-style-type: none"> ▪ University of Illinois at Chicago (Chicago, IL) ▪ Alexian Neuroscience Center (Elk Grove Village, IL) ▪ Director of Illinois Gamma Knife Center ▪ Affiliation to Chicago Cyber Knife LLC
Dr. Piero Andrea Oppido	<ul style="list-style-type: none"> ▪ Neuroendoscopy 	<ul style="list-style-type: none"> ▪ National Cancer Institute “Regina Elena” (Rome, Italy)
Dr. Donald O'Rourke	<ul style="list-style-type: none"> ▪ Brain Tumors 	<ul style="list-style-type: none"> ▪ Clinical Director at the University of Pennsylvania (Philadelphia, PA)
Dr. Ezriel Kornel	<ul style="list-style-type: none"> ▪ Spinal Surgery 	<ul style="list-style-type: none"> ▪ Director, Institute for Neurosciences at Northern Westchester Hospital Center (Mount Kisco, NY) ▪ President-elect New York State Neurosurgical Society ▪ Member Board of Directors, Medical Liability Mutual Insurance ▪ Director for Center for Neurochiropractic Education